Certainly.
It is still early days and there's no question these investments have brought Canada to the forefront of nanomedicine and nanotechnology as applied to health. It is still, in many cases, very experimental, but we see a huge promise for new ways of delivering drugs, for instance, in delivering drugs specifically to tumours through the administration of these drugs via some nanoparticles that will be able to directly target the tumour and not disseminate the drug throughout the body.
There's a lot that we've been funding. I can say that as we develop the field more, more investigators are trained, and more young investigators are coming back from post-doctoral studies abroad and starting to do research in that field.
We see an increasing demand for funding in that area.